Efficacy And Safety Of Deucravacitinib, An Oral, Selective Tyrosine Kinase 2 Inhibitor, In Patients With Moderately To Severely Active Ulcerative Colitis: 12-Week Results From The Phase 2 Lattice-Uc Study
Deucravacitinib
Below is an instruction that describes a task, paired with an input that provides further context. Write a response that appropriately completes the request. ### Instruction: Identify all the mentioned drugs in the given text. Text may or may not contain drug. If they contain more than 1 drug, use ";" as delimiter and join them. ### Input: Efficacy And Safety Of Deucravacitinib, An Oral, Selective Tyrosine Kinase 2 Inhibitor, In Patients With Moderately To Severely Active Ulcerative Colitis: 12-Week Results From The Phase 2 Lattice-Uc Study ### Output: Deucravacitinib